Literature DB >> 23206859

Inhibitors of HIV-1 attachment. Part 11: the discovery and structure-activity relationships associated with 4,6-diazaindole cores.

John A Bender1, Zhong Yang, Betsy Eggers, Yi-Fei Gong, Pin-Fang Lin, Dawn D Parker, Sandhya Rahematpura, Ming Zheng, Nicholas A Meanwell, John F Kadow.   

Abstract

A series of HIV-1 attachment inhibitors containing a 4,6-diazaindole core were examined in an effort to identify a compound which improved upon the potency and oral exposure of BMS-488043 (2). BMS-488043 (2) is a 6-azaindole-based HIV-1 attachment inhibitor which established proof-of-concept for this mechanism in human clinical studies but required high doses and concomitant administration of a high fat meal to achieve efficacious exposures. Based on previous studies in indole and azaindole scaffolds, SAR investigation was concentrated around the key 7-position in the 4,6-diazaindole series and led to the discovery of molecules with 5- to 20-fold increases in potency and three- to seven-fold increases in exposure over 2 in a rat PK studies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23206859     DOI: 10.1016/j.bmcl.2012.10.118

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Authors:  Tao Wang; John F Kadow; Nicholas A Meanwell; Mark Krystal
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120.

Authors:  Radhika Vangala; Sree Kanth Sivan; Saikiran Reddy Peddi; Vijjulatha Manga
Journal:  J Comput Aided Mol Des       Date:  2019-12-02       Impact factor: 3.686

Review 3.  Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.

Authors:  Tao Wang; John F Kadow; Nicholas A Meanwell
Journal:  Med Chem Res       Date:  2021-09-28       Impact factor: 1.965

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.